Phase 3 N=163 Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis
Multiple Sclerosis
Primary: Number of Combined Unique Active Lesions — 0.0; 0.0 lesions
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,301 A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Neoplasms
Primary: Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population…
Phase 1 N=8 Safety, Tolerability and Pharmacokinetic Investigation of GSK3882347 in Healthy Participants.
Urinary Tract Infections
Primary: Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) — 7; 1; 2; 2 Participants
Phase 2 N=282 High-Dose Isoniazid Among Adult Patients With Different Genetic Variants of INH-Resistant Tuberculosis (TB)
Tuberculosis
Primary: Daily Change in log10 Colony-forming Unit (CFU) — -0.06; -0.18; -0.21; -0.15 log10 CFU per mL sputum per day
N/A N=9 FitMi PD Home Therapy for Parkinson's Disease
Parkinson Disease
Primary: Number of Participants That Successfully Used FitMi PD to Exercise at Home — 7 Participants
N/A N=49 Overcoming Pain Through Yoga in the Military
Chronic Low Back Pain · Chronic Neck Pain
Primary: Pain Interference — 4.2; 4.0; 3.9; 3.2 score on a scale
Phase 3 N=235 Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Hepatocellular Carcinoma · Unresectable Hepatocellular Carcinoma
Primary: Progression-free Survival (PFS) — 9.3; 8.4 months — p=0.4
Phase 2 N=48 Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda
Porphyria Cutanea Tarda
Primary: Remission — 6.1; 6.9 months
Phase 3 N=55 Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)
Merkel Cell Carcinoma
Primary: Objective Response Rate (ORR) — 49.1 Percentage of participants
Early Phase 1 N=66 Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics
Antibiotic-associated Diarrhea
Primary: Level of Fecal Short-chain Fatty Acid (SCFA) Acetate — 53.1; 45.2; 42.3; 38.1 micromolar (μM)
Phase 2 N=25 Longitudinal MR Imaging of Pulmonary Function in Patients Receiving Thoracic Radiation Treatment
Radiation Injury
Primary: Change in Pulmonary Function, as Measured by Ventilation Defect Percentage (VDP) — -2.20 Ventilation Defect Percentage (VDP) — p=0.22
N/A N=60 Electromyographic and Acceleromyographic Monitoring in Restricted Arm Movement Surgical Setting
Residual Neuromuscular Blockade
Primary: Accuracy of Values Between Tetragraph and ToFscan — 0; 2 Participants
N/A N=144 Cryoanalgesia to Treat Post-Amputation Phantom Limb Pain: A Department of Defense Funded Multicenter Study
Post-Amputation Phantom Limb Pain
Primary: Change From Baseline in Average Daily Phantom Pain Intensity — 0.5; 0 score on a scale
Phase 3 N=31 Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB
Dystrophic Epidermolysis Bullosa · Recessive Dystrophic Epidermolysis Bullosa · Dominant Dystrophic Epidermolysis Bullosa
Primary: Primary Wound With Complete Wound Healing (100% Wound Closure) on Weeks 22 and 24 or Weeks 24 and 26 — 20.9; 6.7 number of wounds with complete healing — p=0.00192
N/A N=89 Long Duration Activity and Metabolic Control After Spinal Cord Injury
Spinal Cord Injuries
Primary: Acute Gene Regulation: NR4A3 mRNA Expression Pre and Post-Stimulation — 3.235; 2.711; 6.286; 5.772 arbitrary units — p=<0.001